Dermagen

Dermagen Inc. develops peptide therapeutics for topical use based on novel and proprietary antimicrobial peptides (AMPs). We aim to become a leading R&D company in this field, providing innovative and profitable licensing opportunities to select pharmaceutical companies with significant market potential. Dermagen focuses on R&D, initially offering new patented products for dermatological indications. Dermagen has selected its first candidate drug (CD), which has entered the development stage. To help advance the development of our portfolio and bring it to market, we welcome interest from new investors, partners, and collaborators.